Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: Expert Opin Ther Targets. 2019 Jun 5;23(8):647–649. doi: 10.1080/14728222.2019.1628220

Figure 1:

Figure 1:

Schematic of FGL2 function. FGL2 activates the FcγRIIB on antigen presenting cells (APC) which can override PD1 (programmed cell death) blockade, resulting in T-cell inactivation. FcγRIIB blockade will subsequently result in T-cell activation in conjunction with anti-PD1 antibody therapy.